Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia

American Journal of Nephrology

Volumn 21, Issue 6, 2001, Pages 449-454

  Nakamura, Tsukasa ^a   Ushiyama, Chifuyu ^a   Hirokawa, Kaoru ^a   Osada, Shiwori ^b   Shimada, Noriaki ^c   Koide, Hikaru ^c  

^a Misato Junshin Hospital   (Japan)

^b NATIONAL REHABILITATION CENTER FOR PERSONS WITH DISABILITIES   (Japan)

^c KOTO HOSPITAL   (Japan)

Author keywords

Diabetes; Endothelial cell; Endothelin; HMG CoA reductase inhibitor; Microalbuminuria

Indexed keywords

ALBUMIN; CERIVASTATIN; CREATININE; ENDOTHELIN 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIN-1; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PYRIDINES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0035700258     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046648     Document Type: Article

References (31)

1. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes
2. Endothelial dysfunction and pathogenesis of diabetic angiopathy
3. Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria. Relation to glomerular hyperfiltration
4. The pathogenesis of atherosclerosis: A perspective for the 1990
5. Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria
6. Endothelial dysfunction precedes development of microalbuminuria in IDDM
7. Increased plasma levels of endothelin-1 and von Willebrand factor in patients with type 2 diabetes and dyslipidemia
8. A putative role of hypercholesterolemia in progressive glomerular injury
9. Lovastatin inhibits proliferation of rat mesangial cells
10. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment
11. Cerivastatin, a new potent synthetic HMG CoA reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesterolemia
12. Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolaemia
13. Summary of the second report of the National Cholesterol Education Program (NCEP). Expert panel on detection. Evaluation, and treatment of high blood cholesterol in adults
14. Raised serum apolipoprotein (a) in acute diabetic retinopathy
15. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
16. Apolipoproteins in lipoprotein receptor in glomeruli in human kidney disease
17. LDL interaction with proteoglycans isolated from human aortas with different atherosclerotic involvement
18. Effect of lipid reduction on the progression of renal disease: A meta-analysis
19. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia
20. Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuria renal disease
21. Impaired nitric oxide-mediated vasodilatation in patients with noninsulin-dependent diabetes mellitus
22. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
23. Increasing plasma fibrinogen, but unchanged levels of intraplatelet cyclic nucleotides, plasma endothelin-1, factor VII, and neopterine during cholesterol lowering with fluvastatin
24. 2-microalbumin in insulin-dependent diabetes
25. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors
26. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia
27. The role of isoprenoids in vascular smooth muscle: Potential benefits of statins unrelated to cholesterol lowering
28. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects
29. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect. Reduction of mRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells
30. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion